Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) EBT (2016 - 2025)

Historic EBT for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.6 million.

  • Cytosorbents' EBT fell 2901.01% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.5 million, marking a year-over-year increase of 907.27%. This contributed to the annual value of -$22.4 million for FY2024, which is 2545.11% up from last year.
  • Cytosorbents' EBT amounted to -$3.6 million in Q3 2025, which was down 2901.01% from -$4.2 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' EBT peaked at -$1.5 million during Q1 2025, and registered a low of -$12.2 million during Q3 2022.
  • Moreover, its 5-year median value for EBT was -$6.2 million (2023), whereas its average is -$6.4 million.
  • In the last 5 years, Cytosorbents' EBT plummeted by 66289.91% in 2021 and then surged by 8149.25% in 2022.
  • Cytosorbents' EBT (Quarter) stood at -$10.0 million in 2021, then surged by 81.49% to -$1.9 million in 2022, then tumbled by 297.48% to -$7.4 million in 2023, then dropped by 25.31% to -$9.3 million in 2024, then skyrocketed by 61.43% to -$3.6 million in 2025.
  • Its EBT stands at -$3.6 million for Q3 2025, versus -$4.2 million for Q2 2025 and -$1.5 million for Q1 2025.